Your browser doesn't support javascript.
loading
Unravelling 5-oxoprolinuria (pyroglutamic aciduria) due to bi-allelic OPLAH mutations: 20 new mutations in 14 families.
Sass, Jörn Oliver; Gemperle-Britschgi, Corinne; Tarailo-Graovac, Maja; Patel, Nisha; Walter, Melanie; Jordanova, Albena; Alfadhel, Majid; Baric, Ivo; Çoker, Mahmut; Damli-Huber, Aynur; Faqeih, Eissa Ali; García Segarra, Nuria; Geraghty, Michael T; Jåtun, Bjørn Magne; Kalkan Uçar, Sema; Kriewitz, Merten; Rauchenzauner, Markus; Bilic, Karmen; Tournev, Ivailo; Till, Claudia; Sayson, Bryan; Beumer, Daniel; Ye, Cynthia Xin; Zhang, Lin-Hua; Vallance, Hilary; Alkuraya, Fowzan S; van Karnebeek, Clara D M.
Affiliation
  • Sass JO; Bioanalytics & Biochemistry, Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, Rheinbach, Germany; Clinical Chemistry & Biochemistry, Children's Research Center, University Children's Hospital, Zürich, Switzerland; Laboratory of Clinical Biochemistry and Metabol
  • Gemperle-Britschgi C; Clinical Chemistry & Biochemistry, Children's Research Center, University Children's Hospital, Zürich, Switzerland.
  • Tarailo-Graovac M; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada.
  • Patel N; Developmental Genetics Unit, Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Walter M; Laboratory of Clinical Biochemistry and Metabolism, University Children's Hospital, Freiburg, Germany.
  • Jordanova A; Molecular Neurogenomics Group, VIB Department of Molecular Genetics, University of Antwerp, Antwerp, Belgium; Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University, Sofia, Bulgaria.
  • Alfadhel M; Genetics Division, Department of Pediatrics, King Saud bin Abdulaziz University for Health Sciences King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Baric I; Department of Pediatrics, University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia.
  • Çoker M; Metabolism Unit, Department of Pediatrics, Ege University Medical Faculty, Izmir, Turkey.
  • Damli-Huber A; kbo-Kinderzentrum München, München, Germany.
  • Faqeih EA; Children's Hospital, King Fahad Medical City, Riyadh, Saudi Arabia.
  • García Segarra N; Center for Molecular Diseases (CMM), Department of Pediatrics, Centre hospitalier universitaire vaudois (CHUV), Lausanne, Switzerland.
  • Geraghty MT; Metabolic Unit, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
  • Jåtun BM; Barneavdelinga, Ålesund sjukehus, Ålesund, Norway.
  • Kalkan Uçar S; Metabolism Unit, Department of Pediatrics, Ege University Medical Faculty, Izmir, Turkey.
  • Kriewitz M; Kinder- und Jugendmedizin, Verbundkrankenhaus Bernkastel/Wittlich, Wittlich, Germany.
  • Rauchenzauner M; Department of Pediatrics, Hospital Ostallgäu-Kaufbeuren, Kaufbeuren, Germany.
  • Bilic K; Clinical Institute of Laboratory Diagnostics, University Hospital Center Zagreb, Croatia.
  • Tournev I; Department of Neurology, Medical University, Sofia, Bulgaria; Department of Cognitive Science and Psychology, New Bulgarian University, Sofia, Bulgaria.
  • Till C; Bioanalytics & Biochemistry, Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, Rheinbach, Germany.
  • Sayson B; Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Beumer D; Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Ye CX; Laboratory of Clinical Biochemistry and Metabolism, University Children's Hospital, Freiburg, Germany.
  • Zhang LH; Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada; Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada; Child and Family Research Institute, Vancouver, BC, Canada.
  • Vallance H; Child and Family Research Institute, Vancouver, BC, Canada; Department of Pathology, Laboratory Medicine, BC Children's and Women's Hospital, University of British Columbia, Vancouver, Canada.
  • Alkuraya FS; Developmental Genetics Unit, Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • van Karnebeek CD; Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada; Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada; Child and Family Research Institute, Vancouver, BC, Canada.
Mol Genet Metab ; 119(1-2): 44-9, 2016 09.
Article in En | MEDLINE | ID: mdl-27477828
ABSTRACT
Primary 5-oxoprolinuria (pyroglutamic aciduria) is caused by a genetic defect in the γ-glutamyl cycle, affecting either glutathione synthetase or 5-oxoprolinase. While several dozens of patients with glutathione synthetase deficiency have been reported, with hemolytic anemia representing the clinical key feature, 5-oxoprolinase deficiency due to OPLAH mutations is less frequent and so far has not attracted much attention. This has prompted us to investigate the clinical phenotype as well as the underlying genotype in patients from 14 families of various ethnic backgrounds who underwent diagnostic mutation analysis following the detection of 5-oxoprolinuria. In all patients with 5-oxoprolinuria studied, bi-allelic mutations in OPLAH were indicated. An autosomal recessive mode of inheritance for 5-oxoprolinase deficiency is further supported by the identification of a single mutation in all 9/14 parent sample sets investigated (except for the father of one patient whose result suggests homozygosity), and the absence of 5-oxoprolinuria in all tested heterozygotes. It is remarkable, that all 20 mutations identified were novel and private to the respective families. Clinical features were highly variable and in several sib pairs, did not segregate with 5-oxoprolinuria. Although a pathogenic role of 5-oxoprolinase deficiency remains possible, this is not supported by our findings. Additional patient ascertainment and long-term follow-up is needed to establish the benign nature of this inborn error of metabolism. It is important that all symptomatic patients with persistently elevated levels of 5-oxoproline and no obvious explanation are investigated for the genetic etiology.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyroglutamate Hydrolase / Pyrrolidonecarboxylic Acid / Amino Acid Metabolism, Inborn Errors / Glutathione Synthase Type of study: Prognostic_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Mol Genet Metab Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Year: 2016 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyroglutamate Hydrolase / Pyrrolidonecarboxylic Acid / Amino Acid Metabolism, Inborn Errors / Glutathione Synthase Type of study: Prognostic_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Mol Genet Metab Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Year: 2016 Document type: Article